<DOC>
	<DOC>NCT01426802</DOC>
	<brief_summary>The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.</brief_summary>
	<brief_title>Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients who sign the informed consent HbA1c in the range of &gt; 7 to ≤10.5% at Visit 1 Ability to comply with all study requirements Pregnant or lactating women Serious cardiovascular disorders Liver/renal disease or dysfunction Antidiabetic other than metformin, thiazolidine, or αGI or insulin Laboratories values abnormalities as defined by the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metformin</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>T2DM</keyword>
</DOC>